Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Expected to Earn Q1 2024 Earnings of ($0.27) Per Share

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDIFree Report) – Equities researchers at HC Wainwright lowered their Q1 2024 earnings per share estimates for shares of Calidi Biotherapeutics in a research report issued on Thursday, March 21st. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.27) for the quarter, down from their prior estimate of ($0.19). HC Wainwright currently has a “Buy” rating and a $2.00 price objective on the stock. The consensus estimate for Calidi Biotherapeutics’ current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Calidi Biotherapeutics’ Q2 2024 earnings at ($0.25) EPS, Q3 2024 earnings at ($0.21) EPS and FY2024 earnings at ($0.88) EPS.

Separately, Robert W. Baird lowered their price target on shares of Calidi Biotherapeutics from $9.00 to $4.50 and set an “outperform” rating for the company in a research report on Thursday, March 21st.

Get Our Latest Research Report on Calidi Biotherapeutics

Calidi Biotherapeutics Price Performance

Shares of NYSEAMERICAN:CLDI opened at $0.57 on Monday. Calidi Biotherapeutics has a 12 month low of $0.48 and a 12 month high of $13.79.

Calidi Biotherapeutics Company Profile

(Get Free Report)

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors.

Featured Stories

Receive News & Ratings for Calidi Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calidi Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.